Cargando…

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan

Female participants had a higher incidence of headache, nausea, myalgia, arthralgia, redness, pruritus, and inoculation site redness and pruritus (p 0.05). Low grade fever, headache, malaise, myalgia, and inoculation site induration and heat were associated with age group (p 0.05).

Detalles Bibliográficos
Autores principales:	Nishizawa, Toshinori, Jinta, Torahiko, Koyamada, Ryosuke, Uehara, Yuki, Taki, Fumika, Arioka, Hiroko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110989/ https://www.ncbi.nlm.nih.gov/pubmed/35600909 http://dx.doi.org/10.1002/jgf2.545

Ejemplares similares

Health care worker burnout after the first wave of the coronavirus disease 2019 (COVID‐19) pandemic in Japan
por: Matsuo, Takahiro, et al.
Publicado: (2021)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
por: Bauernfeind, Stilla, et al.
Publicado: (2022)

Retrospective evaluation of the symptom-based work restriction strategy of healthcare providers in the first epidemic of COVID-19 at a tertiary care hospital in Tokyo, Japan
por: Shikano, Hiroki, et al.
Publicado: (2022)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Bivalent BNT162b2 mRNA original/omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared with the monovalent COVID-19 booster
por: Wagenhäuser, Isabell, et al.
Publicado: (2023)

Characteristics of participants in a public rubella antibody testing program conducted at a Japan professional football league venue
por: Nishizawa, Toshinori, et al.
Publicado: (2023)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

Protection against Covid-19 by BNT162b2 Booster across Age Groups
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Adverse Reactions and Attitudes Toward the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age in Japan
por: Matsumoto, Naomi, et al.
Publicado: (2023)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Acute myopericarditis following administration of the BNT162b2 booster vaccine against COVID19
por: Sivan, S.K., et al.
Publicado: (2022)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
por: Mofaz, Merav, et al.
Publicado: (2022)

Diffuse large B‐cell lymphoma presenting with cavitary lung disease
por: Hibino, Yukiko, et al.
Publicado: (2020)

Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
por: Imai, Ryosuke, et al.
Publicado: (2021)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
por: Kiewisz, Jolanta, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Third cranial nerve palsy due to COVID-19 infection
por: Iwasaki, Monika, et al.
Publicado: (2023)

Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
por: Li, Rui, et al.
Publicado: (2022)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine
por: Azzi, Lorenzo, et al.
Publicado: (2023)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
por: Hertz, Tomer, et al.
Publicado: (2023)

Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan
por: Igari, Hidetoshi, et al.
Publicado: (2022)

Reversible Cerebral Vasoconstriction Syndrome Associated with Vasospasm of the Colic Arteries and Possibly Coronary Vasospasm
por: Kitamura, Hikaru, et al.
Publicado: (2023)

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
por: Glatman-Freedman, Aharona, et al.
Publicado: (2022)

Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel
por: Muhsen, Khitam, et al.
Publicado: (2021)

Response to tozinameran (BNT162b2) booster in twice-vaccinated kidney transplant and maintenance dialysis patients
por: Ben-Dov, Iddo Z., et al.
Publicado: (2022)

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

Serum C reactive protein predicts humoral response after BNT162b2 booster administration
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine
por: Naaber, Paul, et al.
Publicado: (2022)

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
por: Sauerwein, Kai M.T., et al.
Publicado: (2023)

Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters
por: Piano Mortari, Eva, et al.
Publicado: (2023)

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
por: Dalla Gasperina, Daniela, et al.
Publicado: (2023)

Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees
por: Masson, Letícia Carrijo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pjthpmgp6rp4rrfafl5r155h27